🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Dasatinib

    Takeda

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  2. Dazostinag

    Takeda

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  3. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 2 small molecule active

    1 trial

  4. Dexlansoprazole

    Takeda

    Barrett's Esophagus

    phase 2 small molecule terminated

    1 trial

  5. Docetaxel

    Takeda

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  6. Elritercept

    Takeda

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  7. Elritercept

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    2 trials

  8. Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Ulcerative Colitis or Crohn's Disease

    phase 2 small molecule active

    1 trial

  9. Everolimus

    Takeda

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  10. FST-100

    Takeda

    Acute Viral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  11. FST-100

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  12. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  13. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  14. Febuxostat

    Takeda

    Renal Impairment

    phase 2 small molecule completed

    1 trial

  15. Febuxostat

    Takeda

    Joint Damage

    phase 2 small molecule completed

    1 trial

  16. Febuxostat

    Takeda

    Hyperuricosuria

    phase 2 small molecule completed

    1 trial

  17. Febuxostat

    Takeda

    Hypertension

    phase 2 small molecule completed

    1 trial

  18. Febuxostat

    Takeda

    Angina

    phase 2 small molecule terminated

    1 trial

  19. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  20. GA-GCB

    Takeda

    Gaucher Disease

    phase 2 small molecule completed

    1 trial

  21. GDX012

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  22. GI.1/GII.4 (15/15)

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  23. HGT-1110

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  24. HGT-1111

    Takeda

    Late Infantile Metachromatic Leukodystrophy

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources